IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.52 Million USD | 62.76% |
| 2022 | 12.61 Million USD | -10.13% |
| 2021 | 14.03 Million USD | 16.26% |
| 2020 | 12.07 Million USD | 12.53% |
| 2019 | 10.72 Million USD | 6.94% |
| 2018 | 10.03 Million USD | 7.65% |
| 2017 | 9.31 Million USD | 18.78% |
| 2016 | 7.84 Million USD | 134.04% |
| 2015 | 3.35 Million USD | 95.91% |
| 2014 | 1.71 Million USD | 41.52% |
| 2013 | 1.2 Million USD | -38.97% |
| 2012 | 1.98 Million USD | 197.45% |
| 2011 | 666 Thousand USD | 90.83% |
| 2010 | 349 Thousand USD | -50.46% |
| 2009 | 704.5 Thousand USD | -51.41% |
| 2008 | 1.44 Million USD | 36.87% |
| 2007 | 1.05 Million USD | 228.22% |
| 2006 | 322.75 Thousand USD | 1366.28% |
| 2005 | 22.01 Thousand USD | 93.27% |
| 2004 | 11.38 Thousand USD | 221.09% |
| 2003 | 3547.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 21.91 Million USD | 6.75% |
| 2023 Q2 | 16.97 Million USD | 1.95% |
| 2023 FY | 20.52 Million USD | 62.76% |
| 2023 Q4 | 20.52 Million USD | 7.94% |
| 2023 Q3 | 19.01 Million USD | 12.01% |
| 2023 Q1 | 16.65 Million USD | 32.04% |
| 2022 Q3 | 12.48 Million USD | -0.49% |
| 2022 Q4 | 12.61 Million USD | 1.05% |
| 2022 Q1 | 17.42 Million USD | 24.14% |
| 2022 Q2 | 12.54 Million USD | -28.0% |
| 2022 FY | 12.61 Million USD | -10.13% |
| 2021 Q2 | 13.57 Million USD | 2.18% |
| 2021 Q4 | 14.03 Million USD | -9.02% |
| 2021 FY | 14.03 Million USD | 16.26% |
| 2021 Q3 | 15.42 Million USD | 13.63% |
| 2021 Q1 | 13.28 Million USD | 10.07% |
| 2020 Q1 | 9.99 Million USD | -6.84% |
| 2020 Q2 | 10.13 Million USD | 1.41% |
| 2020 FY | 12.07 Million USD | 12.53% |
| 2020 Q3 | 10.68 Million USD | 5.39% |
| 2020 Q4 | 12.07 Million USD | 13.02% |
| 2019 FY | 10.72 Million USD | 6.94% |
| 2019 Q4 | 10.72 Million USD | 2.87% |
| 2019 Q3 | 10.42 Million USD | 0.34% |
| 2019 Q2 | 10.39 Million USD | -1.24% |
| 2019 Q1 | 10.52 Million USD | 4.9% |
| 2018 Q2 | 10.41 Million USD | 15.31% |
| 2018 Q3 | 10.59 Million USD | 1.76% |
| 2018 FY | 10.03 Million USD | 7.65% |
| 2018 Q4 | 10.03 Million USD | -5.36% |
| 2018 Q1 | 9.03 Million USD | -3.06% |
| 2017 Q1 | 6.52 Million USD | -16.78% |
| 2017 FY | 9.31 Million USD | 18.78% |
| 2017 Q4 | 9.31 Million USD | -10.2% |
| 2017 Q3 | 10.37 Million USD | 92.22% |
| 2017 Q2 | 5.39 Million USD | -17.32% |
| 2016 FY | 7.84 Million USD | 134.04% |
| 2016 Q4 | 7.84 Million USD | -9.02% |
| 2016 Q3 | 8.62 Million USD | 87.78% |
| 2016 Q2 | 4.59 Million USD | 52.15% |
| 2016 Q1 | 3.01 Million USD | -9.96% |
| 2015 Q1 | 1.49 Million USD | -12.57% |
| 2015 Q3 | 1.78 Million USD | 21.36% |
| 2015 FY | 3.35 Million USD | 95.91% |
| 2015 Q2 | 1.47 Million USD | -1.74% |
| 2015 Q4 | 3.35 Million USD | 87.89% |
| 2014 FY | 1.71 Million USD | 41.52% |
| 2014 Q3 | 702 Thousand USD | -9.77% |
| 2014 Q2 | 778 Thousand USD | -10.78% |
| 2014 Q1 | 872 Thousand USD | -27.87% |
| 2014 Q4 | 1.71 Million USD | 143.73% |
| 2013 Q1 | 1.34 Million USD | -32.1% |
| 2013 FY | 1.2 Million USD | -38.97% |
| 2013 Q4 | 1.2 Million USD | 20.06% |
| 2013 Q3 | 1 Million USD | -8.87% |
| 2013 Q2 | 1.1 Million USD | -17.84% |
| 2012 Q1 | 1.39 Million USD | 109.61% |
| 2012 FY | 1.98 Million USD | 197.45% |
| 2012 Q4 | 1.98 Million USD | 58.23% |
| 2012 Q3 | 1.25 Million USD | -2.42% |
| 2012 Q2 | 1.28 Million USD | -8.09% |
| 2011 Q1 | 278 Thousand USD | -20.34% |
| 2011 Q2 | 382 Thousand USD | 37.41% |
| 2011 Q3 | 376 Thousand USD | -1.57% |
| 2011 Q4 | 666 Thousand USD | 77.13% |
| 2011 FY | 666 Thousand USD | 90.83% |
| 2010 Q1 | 964 Thousand USD | 36.83% |
| 2010 FY | 349 Thousand USD | -50.46% |
| 2010 Q3 | 315 Thousand USD | -69.24% |
| 2010 Q2 | 1.02 Million USD | 6.22% |
| 2010 Q4 | 349 Thousand USD | 10.79% |
| 2009 Q3 | 797 Thousand USD | -52.68% |
| 2009 Q2 | 1.68 Million USD | 4.65% |
| 2009 Q4 | 704.5 Thousand USD | -11.61% |
| 2009 Q1 | 1.6 Million USD | 10.99% |
| 2009 FY | 704.5 Thousand USD | -51.41% |
| 2008 Q2 | 1.41 Million USD | -9.88% |
| 2008 Q4 | 1.44 Million USD | -8.45% |
| 2008 Q3 | 1.58 Million USD | 11.91% |
| 2008 Q1 | 1.57 Million USD | 48.24% |
| 2008 FY | 1.44 Million USD | 36.87% |
| 2007 Q2 | 780.78 Thousand USD | 163.83% |
| 2007 Q4 | 1.05 Million USD | 19.56% |
| 2007 Q1 | 295.94 Thousand USD | -8.31% |
| 2007 FY | 1.05 Million USD | 228.22% |
| 2007 Q3 | 886.04 Thousand USD | 13.48% |
| 2006 Q2 | 263.37 Thousand USD | 1037.19% |
| 2006 Q4 | 322.75 Thousand USD | -9.55% |
| 2006 Q1 | 23.16 Thousand USD | 5.22% |
| 2006 FY | 322.75 Thousand USD | 1366.28% |
| 2006 Q3 | 356.83 Thousand USD | 35.48% |
| 2005 Q2 | 17.32 Thousand USD | 14.41% |
| 2005 Q3 | 19.55 Thousand USD | 12.87% |
| 2005 Q4 | 22.01 Thousand USD | 12.59% |
| 2005 FY | 22.01 Thousand USD | 93.27% |
| 2005 Q1 | 15.14 Thousand USD | 32.94% |
| 2004 FY | 11.38 Thousand USD | 221.09% |
| 2004 Q1 | 3547.00 USD | 0.0% |
| 2004 Q2 | 6610.00 USD | 86.35% |
| 2004 Q3 | 9356.00 USD | 41.54% |
| 2004 Q4 | 11.38 Thousand USD | 21.73% |
| 2003 FY | 3547.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HST Global, Inc. | 593.59 Thousand USD | -3358.43% |
| Regen BioPharma, Inc. | 5.45 Million USD | -276.153% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2915.272% |
| CytoDyn Inc. | 127.89 Million USD | 83.948% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 73.483% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1268947.457% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -236.436% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -116.873% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -14347.377% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -4317.698% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | 7.16 Million USD | -186.527% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 72.599% |
| SQZ Biotechnologies Company | 50.03 Million USD | 58.974% |
| Resverlogix Corp. | 67.39 Million USD | 69.54% |
| Neon Bloom, Inc. | 1.22 Million USD | -1574.179% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -251.366% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -449.741% |
| Mesoblast Limited | 188.44 Million USD | 89.106% |
| GB Sciences, Inc. | 5.41 Million USD | -278.935% |
| Regen BioPharma, Inc. | 5.45 Million USD | -276.153% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 71.673% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -460.111% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -11.55% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2347.623% |
| ContraFect Corporation | 32.53 Million USD | 36.894% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -74.297% |
| BioStem Technologies, Inc. | 15.9 Million USD | -29.075% |
| LadRx Corporation | 2.2 Million USD | -832.912% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -10107.542% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -239.378% |
| CSL Limited | 18.62 Billion USD | 99.89% |
| Biomind Labs Inc. | 1.49 Million USD | -1269.868% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -715.832% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 65.213% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2438.224% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 61.488% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -114.245% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 75.247% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -433.024% |
| Marizyme, Inc. | 26.67 Million USD | 23.042% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -440.237% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -85.862% |
| Zenith Capital Corp. | 27.56 Thousand USD | -74364.072% |
| Intellipharmaceutics International Inc. | 12 Million USD | -70.95% |
| Halberd Corporation | 728.71 Thousand USD | -2717.135% |
| Genus plc | 485 Million USD | 95.767% |
| Pharming Group N.V. | 244.07 Million USD | 91.589% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -921.277% |
| IMV Inc. | 37.93 Million USD | 45.881% |
| Affymax, Inc. | 8.87 Million USD | -131.417% |
| SYBLEU INC | 681.41 Thousand USD | -2912.71% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1097.725% |
| Enzolytics Inc. | 365.26 Million USD | 94.38% |
| argenx SE | 444.95 Million USD | 95.386% |
| AVAX Technologies, Inc. | 3.99 Million USD | -414.029% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -436.335% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -74733.23% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -1802.174% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -49013.615% |
| Cell Source, Inc. | 15.8 Million USD | -29.875% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -870.607% |
| Q BioMed Inc. | 8.13 Million USD | -152.418% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -900.651% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 59.158% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -298.928% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -936.134% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 82.708% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -127.036% |
| Rebus Holdings, Inc. | 5.24 Million USD | -291.625% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -30572.803% |
| Skye Bioscience, Inc. | 14.07 Million USD | -45.883% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1331.729% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -657.069% |
| ONE Bio Corp. | 27.49 Million USD | 25.338% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -257.286% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1530.33% |
| Agentix Corp. | 2.51 Million USD | -717.708% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 17.041% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -72.468% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -8501.993% |
| Kadimastem Ltd | 3.5 Million USD | -485.728% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -4769.677% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -45830.285% |
| NovAccess Global Inc. | 7.86 Million USD | -161.159% |
| Itoco Inc. | 1.65 Million USD | -1141.81% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1210.604% |
| Qrons Inc. | 1.48 Million USD | -1278.976% |
| Mobile Lads Corp. | 1.31 Million USD | -1462.927% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.452% |
| International Stem Cell Corporation | 5.27 Million USD | -289.028% |
| Bioxytran, Inc. | 3.24 Million USD | -531.759% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -3180.394% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -344.627% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 49.924% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 7.797% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -913.584% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -274.754% |
| Neutra Corp. | 973.52 Thousand USD | -2008.72% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 29.247% |
| PureTech Health plc | 125.58 Million USD | 83.653% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -446.402% |
| IXICO plc | 1.9 Million USD | -980.308% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 80.131% |
| CSL Limited | 18.62 Billion USD | 99.89% |
| Cellectis S.A. | 249.36 Million USD | 91.768% |